Table 3.
Antibodies targeting CCR2-CCL2 axis.
| Product | Developer | Stage | Target | Indications | Status | Reference/Clinical Trail No. |
|---|---|---|---|---|---|---|
| Anti-CCR2 | Pfizer, Amgen, | Pre | CCR2 | Solid tumor, Inflammation | Active | US9238691B2 |
| Anti-CCR2 | MRC, U.Regensburg | Pre | CCR2 | MS, RA | Active | US9068002B2 |
| Anti-CCR2 | Sorrento | Pre | CCR2 | MS | Inactive | (186) |
| Anti-CCR2, CSF-1R | Elstar | Pre | CCR2, CSF-1R | Inflammation | Not Clear | WO1997031949A1 |
| CCL2-LPM | Osprey Pharmaceuticals | I | CCR2 | IgA nephropathy | Inactive | NCT00856674 |
| Plozalizumab (MLN1202) | Takeda Pharmaceuticals | II | CCR2 | Solid tumors | Inactive | NCT02723006 |
| Plozalizumab (MLN1202) | Takeda Pharmaceuticals | II | CCR2 | Atherosclerosis | Inactive | NCT00715169 |
| VET2-L2 (oncolytic virus) | Astellas Pharma, KaliVir Immunotherapeutics | Pre | CCR2, leptin, IL-2 | Solid tumors | Active | (187) |
| ABN912 | Novartis | I | CCL2 | RA | Inactive | (188) |
| Carlumab (CNTO 888) | Johnson & Johnson | II | CCL2 | Solid tumor, Prostate cancer | Inactive | NCT01204996, NCT00992186 (189), |
| Carlumab (CNTO 888) | Johnson & Johnson | II | CCL2 | Idiopathic pulmonary fibrosis, | Inactive | NCT00786201 |
| ABN912 | Novartis | Pre | CCL2 | Tumor | Not Clear | (190) |
| Anti-CCL2 | Shire Human Genetic Therapies | Pre | CCL2 | Scleroderma | Not Clear | WO2013177264A1 |